Showing Results for
- Academic Journals (21)
Search Results
- 21
Academic Journals
- 21
- Search Terms:
- 1From: Pharmacogenomics. (Vol. 5, Issue 3) Peer-ReviewedThe choice of cancer therapy for an individual patient has traditionally been determined by the type of primary tumor, its level of differentiation, the degree and sites of spread in the body, and the likely risk of...
- 2From: Pharmacogenomics. (Vol. 5, Issue 3) Peer-ReviewedThe cytochrome P450 3A (CYP3A) subfamily members are the most abundant and important drug-metabolizing enzymes in humans, and wide interindividual variability in CYP3A expression and function is present. CYP3A4 alone...
- 3From: Pharmacogenomics. (Vol. 5, Issue 3) Peer-ReviewedThe unraveling of genetic defects associated with disorders in lipid metabolism has contributed to the understanding of lipoprotein metabolism and the pathophysiological consequences of a particular mutation. The...
- 4From: Pharmacogenomics. (Vol. 5, Issue 3) Peer-ReviewedProstate cancer continues to be the second leading cause of cancer in men. Diagnosis of the disease exceeds that of lung cancer among men in the US, with 220,900 new cases and 28,900 deaths in 2003. Researchers at...
- 5From: Pharmacogenomics. (Vol. 5, Issue 3) Peer-ReviewedThe UK's National Cancer Research Institute (NCRI) has launched a groundbreaking initiative aimed at providing an informatics platform that will enable a new level of cancer data exchange in a format that will be...
- 6From: Pharmacogenomics. (Vol. 5, Issue 3) Peer-ReviewedDrug disposition is highly dependent on the interplay between drug metabolism and transport in organs such as the intestine, kidney, and liver. Genetically determined variation in drug transporter function or expression...
- 7From: Pharmacogenomics. (Vol. 5, Issue 3) Peer-ReviewedKeystone Symposium, 'Genomic Biomarkers Impact on Drug Discovery and Clinical Practice' January 26-30, 2004, Santa Fe, New Mexico, USA Genomic biomarkers (molecular profiles of disease phenotypes and drug response)...
- 8From: Pharmacogenomics. (Vol. 5, Issue 3) Peer-ReviewedOdom DT, Zizlsperger N, Gordon DB et al.: Science 303(5662), 1378-1381 (2004). Chromatin immunoprecipitation was used in combination with promoter microarrays to identify systematically the genes occupied by the...
- 9From: Pharmacogenomics. (Vol. 5, Issue 3) Peer-ReviewedMutations in a gene linked to the progression of colon and other cancers have been discovered by scientists at the Johns Hopkins Kimmel Cancer Center and Howard Hughes Medical Institute. The gene in question, PIK3CA,...
- 10From: Pharmacogenomics. (Vol. 5, Issue 3) Peer-ReviewedPharmacoproteomics is the use of proteomic technologies in drug discovery and development. Along with pharmacogenomics and pharmacogenetics, pharmacoproteomics will play an important role in the development of...
- 11From: Pharmacogenomics. (Vol. 5, Issue 3) Peer-ReviewedTwo international research teams studying genetic susceptibility to diabetes Type 2 in Finnish and Ashkenazi Jewish populations have linked variants in the regulatory region of the hepatocyte nuclear factor 4[alpha]...
- 12From: Pharmacogenomics. (Vol. 5, Issue 3) Peer-ReviewedResearchers at Oxford University have reported that the effectiveness of nicotine patch therapy appears to be related to the genotype in women, but not in men. The findings, which were published in the British...
- 13From: Pharmacogenomics. (Vol. 5, Issue 3) Peer-ReviewedIn an effort to compile the US's first public database of standardized, clinically annotated gene expression data, the International Genomics Consortium (IGC), a non-profit medical research organization, has launched...
- 14From: Pharmacogenomics. (Vol. 5, Issue 3) Peer-ReviewedThe human cytochrome P450 (CYP) complement of heme-thiolate enzymes is reviewed. Of the 57 individual P450s characterized in Homo sapiens thus far, it is apparent that approximately one-half are associated with the...
- 15From: Pharmacogenomics. (Vol. 5, Issue 3) Peer-ReviewedBioTrends 2004 (RNAi and siRNA session), IIR Deutschland GmbH February 16-18, 2004, Berlin, Germany Introduction Gene silencing by RNA interference (RNAi) technolo gies has made considerable progress in the last...
- 16From: Pharmacogenomics. (Vol. 5, Issue 3) Peer-ReviewedHurt EM, Wiestner A, Rosenwald A et al.: Cancer Cell 5(2), 191-199 (2004). The oncogene c-maf is translocated in ~ 5-10% of multiple myelomas. The authors observed c-maf expression in myeloma cell lines lacking c-maf...
- 17From: Pharmacogenomics. (Vol. 5, Issue 3) Peer-ReviewedGentronix is an innovative biotechnology company with the aim of providing cell-based assays and systems to ease or remove some of the current bottlenecks in preclinical drug discovery and development. Gentronix's first...
- 18From: Pharmacogenomics. (Vol. 5, Issue 3) Peer-Reviewedvan Eijk MJ, Broekhof JL, van der Poel HJ et al.: Nucleic Acids Res. 32(4), e47 (2004). SNPWave is a novel SNP genotyping technology to detect various subsets of sequences in a flexible fashion in a fixed detection...
- 19From: Pharmacogenomics. (Vol. 5, Issue 3) Peer-ReviewedAdvancements in pharmacogenomics and chemoprevention promise to reduce cancer incidence and mortality, but utilization will undoubtedly be accompanied with ethical and legal issues that largely remain unexplored or...
- 20From: Pharmacogenomics. (Vol. 5, Issue 3) Peer-ReviewedProstate cancer is the most common non-skin cancer in the US; it is the second leading cause of death from cancer among US men, and the seventh leading cause of death in the US. This review examines the recent...